Ascendis Pharma A/S (ASND)

Ascendis Pharma reported a net loss of €34 million for Q4 2025, and a full-year 2025 net loss of €228 million. The FDA granted accelerated approval to Ascendis Pharma's YUVIWEL for achondroplasia in children. Ascendis Pharma completed its transition to a direct listing of its ordinary shares on Nasdaq. The company reported a Q1 2026 EPS of €0.27, surpassing the forecast of €0.18, but revenue of €247 million fell short of the €269.95 million forecast. Ascendis Pharma decided to discontinue internal oncology development of TransCon IL-2 β/γ to focus on its endocrine pipeline and combination therapies.

Ascendis Pharma's Q1 2026 earnings call mentioned "normal seasonality" for its products, particularly YORVIPATH. SKYTROFA's sequential performance in Q1 2026 reflected consistent underlying demand with an expected drawdown in channel inventory built in Q4. Demand might see some fluctuations related to inventory cycles and potentially patient enrollment patterns, but a clear, detailed seasonal trend is not explicitly defined beyond the general mention of "normal seasonality."

Ascendis Pharma A/S is a Denmark-based biopharmaceutical company focused on developing therapies for rare diseases and serious chronic conditions using its TransCon technology platform. The company's primary focus areas are endocrinology and oncology. Major marketed products include SKYTROFA for growth hormone deficiency, YORVIPATH for chronic hypoparathyroidism and YUVIWEL for achondroplasia. The company also has a pipeline of product candidates in clinical development.

Ascendis Pharma A/S is headquartered in Copenhagen, Denmark, with additional facilities in Europe and the United States. The company has a global presence, with commercial operations and clinical studies spanning North America, Europe, and Asia. Its products are authorized in various countries and regions, including the United States, and YORVIPATH is commercially available or through named patient programs in 35 countries. The majority of its revenue is derived from the United States.

Ascendis Pharma's brand reputation is largely positive, driven by its focus on science, patients, and passion, and its innovative TransCon technology platform. FDA approvals for TransCon products, positive clinical trial data, a strategic roadmap focused on growth, and achieving profitability in Q1 2026 contribute to its positive reputation. No significant negative events impacting its brand reputation in the past year were identified.

Ascendis Pharma A/S exhibits a strong concentration of institutional investors. As of May 1, 2026, institutional ownership stands at approximately 81.7%. Major institutional shareholders include RA Capital Management LP, Westfield Capital Management Co LP, and Avoro Capital Advisors LLC. Individual insider ownership is minimal, reported at 0.78%, and retail investor ownership is reported at 0.00% as of July 25, 2025.